Search

Treosulfan

Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation. … [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

Faricimab

[L40026] It received subsequent approval for the same indications in Canada in May 2022. … [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026]

Methoxy PEG-12 retinamide

Technetium Tc-99m tilmanocept

DTPA serves as a chelating agent for technetium Tc 99m to bind [FDA Label]. … Food and Drug Administration (FDA) for the imaging of lymph nodes with or without scintigraphic imaging.

Tusamitamab ravtansine

Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).

Levetiracetam

having generally narrow therapeutic indexes and a propensity for involvement in drug interactions. … It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).

Arsenic trioxide

The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.

Benzatropine

potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. … Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease.

Edaravone

However, the drug manufacturer, Mitsubishi Tanabe Pharma, withdrew the Marketing Authorization Application (MAA) for edaravone from the European market on May 24, 2019, in response to the request made … [L44007] It was later approved for the treatment of amyotrophic lateral sclerosis (ALS) in Japan and South Korea in 2015, followed by the FDA approval in May 2017 [L41810] and Health Canada approval in

Telmisartan

[A1489,A1490] Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.[A1492] … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.